Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Contributed by: Business Wire

Logo

Tags

Health

Consumer

Neurology

Women

Other Health

Pharmaceutical

Biotechnology

Lilly

More Like This

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

Organon to Present New Research on Access and Value at ISPOR 2026

Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

PR Newswire associated0

Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in Europe